Stockreport

CG Oncology (CGON): Assessing Valuation Following Analyst Coverage and Positive Phase 3 Trial Results [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF This attention is supported by promising late-stage trial results for its lead bladder cancer therapy and anticipation of an FDA review next year. See our latest analy [Read more]